Differences in Cymbalta & Pristiq
Cymbalta and Pristiq are prescription drugs classified as serotonin norepinephrine reuptake inhibitors. Cymbalta is the brand name of duloxetine and Pristiq is the brand name of desvenlafaxine. Both of the medications block the reabsorption of serotonin and norepinephrine in the brain. Cymbalta weakly inhibits a third chemical called dopamine. This leads to the normalization of the levels of these chemicals. Although these medications are similar, they differ in their use and effect on the patient.
If you are experiencing serious medical symptoms, seek emergency treatment immediately.
Indications
Pristiq and Cymbalta are indicated for the treatment of major depressive disorder. Cymbalta is also indicated for the treatment of generalized anxiety disorder and the management of fibromyalgia. Cymbalta treats pain and tingling caused by diabetic neuropathy, which is nerve damage that may occur in uncontrolled diabetes.
Dosage and Administration
Seroquel & Elevated Liver Enzymes
Learn More
Pristiq is available as extended release tablets in 50 and 100 mg doses. The usual dose is 50 mg and may be increased as needed up to 400 mg a day, according to the “Drug Information Handbook.” The tablet should be swallowed whole and may be taken with or without food. Cymbalta is a delayed release, enteric-coated capsule available in 20 mg, 30 mg and 60 mg. The capsule must be swallowed whole with a full glass of water. The usual dose for major depressive disorder is 40 to 60 mg as a single daily dose or in two divided doses. Patients with generalized anxiety disorder are administered 30 to 60 mg a day. The usual dose in patients with diabetic neuropathy is 60 mg once daily. Patients with fibromyalgia are given 30 mg a day for the first week of therapy and then increased to 60 mg a day.
- Pristiq is available as extended release tablets in 50 and 100 mg doses.
- The usual dose for major depressive disorder is 40 to 60 mg as a single daily dose or in two divided doses.
Creatinine Clearance
Dosage adjustments are determined by the patient’s creatinine clearance, which measures how well the patient eliminates wastes from the body.
Pristiq does not require dosage adjustment if the creatinine clearance is above 50 mL per minute. If the creatinine clearance is between 30 and 50 mL per minute, the maximum daily dose is 50 mg. The maximum dose is 50 mg every other day when the creatinine clearance falls below 30 mL per minute. Patients on hemodialysis must not receive more than 50 mg ever other day.
In the case of Cymbalta, it is not recommended for use in patients who have creatinine clearance less than 30 mL per minute or in end stage renal disease, states RxList.com 2. In patients with mild to moderate kidney impairment, lower starting doses may be needed and increased according to the patient’s response.
- Dosage adjustments are determined by the patient’s creatinine clearance, which measures how well the patient eliminates wastes from the body.
- The maximum dose is 50 mg every other day when the creatinine clearance falls below 30 mL per minute.
Liver Function
What Are the Sexual Side Effects of Cymbalta?
Learn More
Pristiq requires dosage adjustment in patients with liver impairment. The initial dose is 50 mg once daily with a maximum dose of 100 mg a day. Cymbalta, on the other hand, is not recommended for use in patients with liver impairment.
Related Articles
References
- "Drug Information Handbook"; Charles F. Lacy, Lora L. Armstrong, et al.; 2009
- RxList.com: Cymbalta
- National Center for Biotechnology Information. PubChem Database. Duloxetine hydrochloride, CID=60834.
- U.S. National Library of Medicine DailyMed. Label: Duloxetine—duloxetine hydrochloride capsule, delayed release. Updated September 9, 2019.
- Osani MC, Bannuru RR. Efficacy and safety of duloxetine in osteoarthritis: a systematic review and meta-analysis. Korean J Intern Med. 2019;34(5):966–973. doi:10.3904/kjim.2018.460
- U.S. National Library of Medicine MedlinePlus. Duloxetine. Updated July 15, 2018.
- Wang ZY, Shi SY, Li SJ, et al. Efficacy and safety of duloxetine on osteoarthritis knee pain: A meta-analysis of randomized controlled trials. Pain Med. 2015;16(7):1373-85. doi:10.1111/pme.12800
Resources
Writer Bio
Karla Casco began writing in 2010, focusing her work on diseases and treatments and their side effects. She has also created patient handouts, PowerPoint presentations and journal clubs. Karla has a doctorate in pharmacy from St. John's University and holds a pharmacy license for the state of New York.